Freeform Search

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Term: L14 same l12

Display: 10 **Documents in Display Format:** - **Starting with Number** 1

Generate: ○ **Hit List** ◉ **Hit Count** ○ **Side by Side** ○ **Image**

Search Clear Interrupt

Search History

DATE: Friday, July 16, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ			
L15	L14 same l12	2	L15
L14	modi$ or revers$	3611935	L14
L13	L12 same l6	6	L13
L12	l9 with l1	21	L12
L11	l9 same l3	4	L11
L10	L9 with l3	3	L10
L9	surface potential or zeta potential	23015	L9
L8	L7 same l5	28	L8
L7	surface	7796737	L7
L6	polyanionic or anionic or negativ$	1210811	L6
L5	L4 with l3	221	L5
L4	DNA or nucleic or plasmid	246149	L4
L3	L2 with l1	778	L3
L2	neutral$	688451	L2
L1	cationic lipid or cationic amphiphile or cationic liposome	9388	L1

END OF SEARCH HISTORY

First Hit Previous Doc Next Doc Go to Doc#

Generate Collection Print

L8: Entry 6 of 28 File: PGPB Nov 14, 2002

DOCUMENT-IDENTIFIER: US 20020169138 A1
TITLE: Delivery vehicles for bioactive agents and uses thereof

Summary of Invention Paragraph:
[0006] Additionally, it is known that the transfection activity of cationic liposomes is interfered with by serum components which presumably neutralize the unpaired positive charges in the complexes which are essential for binding of DNA/lipid complexes to the cell surface. See, e.g., Felgner, P. L. et al. Nature 337:387-388, 1989; Felgner, P. L., et al. Proc. Natl. Acad. Sci. USA 84:7413-7417, 1987; and Gao, X. and Huang, L., Biochem. Biophys. Res. Comm. 179:280-285, 1991. Because of this problem alone, the use of cationic liposomes for gene transfer is limited to the situation where a minimal amount of serum is present; accordingly, cationic liposomes as an in vivo delivery system are of limited value.

Previous Doc Next Doc Go to Doc#

First Hit Previous Doc Next Doc Go to Doc#

Generate Collection Print

L11: Entry 2 of 4 File: PGPB Mar 21, 2002

DOCUMENT-IDENTIFIER: US 20020034537 A1
TITLE: Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites

Summary of Invention Paragraph:
[0018] This McDonald et al. patent describes the use of cationic liposomes that may include both neutral and cationic lipids, for example, having 5 mol % or more of cationic lipids or, specifically, having neutral lipids in an amount of about 45% and cationic lipids in an amount of about 55%. While McDonald et al. indicates that cationic liposomes have a zeta potential of greater than 0 mV, this patent does not teach any specific zeta potential or isoelectric point, or ranges thereof, as being preferred for the selective targeting of angiogenic endothelial cells. McDonald et al. also does not indicate the preferred upper limit of cationic lipid to use in the cationic liposome composition for selective targeting of angiogenic endothelial cells. 100161 Thurston et al. (1998) also describes the targeting of endothelial cells in tumors and chronic inflammation in mice using cationic liposomes. Thurston uses cationic liposomes having 55 mol % of cationic component. Thurston does not disclose the specific zeta potential or isoelectric point or ranges thereof for selective targeting of endothelial cells in tumors or chronic inflammation in mice.

Previous Doc Next Doc Go to Doc#